To better understand the molecular mechanism underlying CACNA2D3-enhanced ESCC cisplatin sensitivity, we compared the gene expression profiles of CACNA2D3 stably overexpressed KYSE30 cells with those of control cells using RNA-seq after cisplatin treatment, and identified 2439 DEGs (FDR < 0.05, |log2 fold change| ≥1) between the two groups. Here, CACNA2D3 is linked to esophageal squamous cell carcinoma.